INNOCARE collaborates with Cannovia "NewCo" for international expansion, potentially receiving over $0.5 billion in milestone payments.

① INNOCARE and Kangnuoya will collectively receive an initial and recent payment of 17.5 million USD at a ratio of 50% each, and will also acquire minority shares in Prolium; ② In recent years, the NewCo model trade boom has emerged, which has dual attributes of financing and business development, providing innovative drug companies with an alternative path to go abroad, apart from the traditional license out.

cls.cnJan 21 00:09 ET

The domestic sales of the flagship products have increased significantly, and R&D expenses have decreased by thirty percent. JUNSHI BIO expects losses to narrow by more than forty percent in 2024.

① JUNSHI BIO also announced that Toripalimab has been approved for marketing by the Australian Therapeutic Goods Administration, and this drug will become the first and only tumor immunotherapy drug for nasopharyngeal carcinoma in Australia. ② Regarding the reasons for revenue growth, JUNSHI BIO explained that it is mainly due to the increase in sales revenue of commercialized Pharmaceuticals compared to the same period last year. As of the end of the reporting period, the company has four commercialized Pharmaceuticals.

cls.cnJan 17 09:05 ET

The US stock market fluctuated and then declined, Apple fell by 4%, Taiwan Semiconductor's ADR once rose over 7%, and Luxury Goods stocks along with European and American government bonds increased.

In December, USA's retail sales growth was weaker than expected, but the Philadelphia January manufacturing Index reached its highest level in nearly four years. Federal Reserve Board member Waller predicted that there might be up to four interest rate cuts this year, which lowered USA Treasury yields and the dollar. The S&P experienced its first decline in four days, previously boosted by Banks' Earnings Reports. Taiwan Semiconductor's quarterly report confirmed AI demand, leading to most chip stocks rising. Luxury Goods giant Richemont's earnings surpassed expectations, causing a collective increase among peers that pushed French stocks up over 2%. The China concept index rose against the trend, with DouYu increasing by about 28%. The yen approached 155, Bitcoin hovered around $0.1 million, oil prices fell from a six-month high, and Gold reached its highest in five weeks. As a cold wave hit, Henry Hub Natural Gas surged over 4%.

wallstreetcnJan 16 19:08 ET

Sales growth of core varieties: REMEGEN's revenue in 2024 is expected to increase by more than 50% year-on-year, but it has not yet achieved profitability.

① The company has increased its R&D investment, while sales revenue of Tai Tasi Pu and Vidi Situt Monoclonal Antibody has grown rapidly, with the product gross margin continuing to rise and the sales expense ratio significantly decreasing. Therefore, it is expected that the company will report a net loss in 2024, showing a trend of reduced losses; ② The company's Phase III clinical trial for IgAN of Tai Tasi Pu in China has concluded, and data readout is expected in the first half of 2025.

cls.cnJan 16 08:15 ET

Zai Lab to Seek China Approval for Cervical Cancer Therapy After Positive Trial Data

Seeking AlphaJan 15 08:02 ET

WUXI XDC's net income for 2024 is expected to increase by 260%. WUXI APPTEC recently cashed out 2.4 billion Hong Kong dollars at a high point | Quick read of the announcement.

In 2024, WUXI XDC expects total revenues, Net income, and adjusted Net income to grow by over 85%, 260%, and 170% year-on-year, respectively; According to the latest data from Frost & Sullivan, it is projected that by 2030, the Global market size for ADC and XDC will reach 66.2 billion US dollars.

cls.cnJan 15 00:06 ET